Table 1.
Clinical Features of the Study Population
| Nonsteatosis (24) | Steatosis (56) | p-value | |
|---|---|---|---|
| Age (years) |
15.2±3.6 |
13.3±3.0 |
0.01 |
| Sex% (M/F) |
42/58 |
47/53 |
0.20 |
| Ethnicity% (C/AA/H/A) |
46/33/17/4 |
35/9/52/4 |
0.008 |
| z-score BMI |
1.73±1.21 |
2.38±0.35 |
0.0006 |
|
Glucose metabolism and lipids | |||
| GT% (NGT/IGT/T2D) |
75/21/4 |
64/32/4 |
0.59 |
| Fasting glucose (mg/dl) |
91.8±9.9 |
95.5±11.0 |
0.16 |
| 2-h glucose (mg/dl) |
118.0±33.4 |
132.6±32.0 |
0.04 |
| WBISI |
2.58±1.89 |
1.34±1.10 |
0.0006 |
| IGI |
4.65±2.94 |
4.88±2.88 |
0.45 |
| DI |
8.27±4.65 |
5.90±5.39 |
0.009 |
| Triglycerides (mg/dl) |
94.3±63.0 |
152.6±112.6 |
0.001 |
| Cholesterol (mg/dl) |
159.0±40.0 |
162.3±34.4 |
0.56 |
| HDL (mg/dl) |
47.3±12.2 |
39.9±8.9 |
0.007 |
| LDL (mg/dl) |
93.5±36.8 |
90.4±28.5 |
0.74 |
| Adiponectin (μg/mL) |
10.9±6.2 |
6.6±2.8 |
0.0009 |
|
Liver function | |||
| HFF% |
1.57±0.89 |
22.4±11.2 |
<0.001 |
| ALT (mU/L) |
18.7±9.4 |
57.3±49.5 |
<0.001 |
| AST (mU/L) |
22.4±5.1 |
39.9±30.4 |
<0.001 |
| CK-18 (U/L) | 109.4±33.5 | 204.4±134.2 | <0.001 |
Continuous variables are shown as mean and standard deviation.
M, male; F, female; C, Caucasians; AA, African Americans; H, Hispanics; A, Asians; BMI, body mass index; GT, glucose tolerance; NGT, normal glucose tolerance; IGT, impaired glucose tolerance; T2D, type 2 diabetes; WBISI, whole-body insulin sensitivity index; IGI, insulinogenic index; DI, disposition index; HDL, high density lipoprotein; LDL, low density lipoprotein; HFF%, hepatic fat content; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK-18, caspase-generated CK-18 fragments.